SCHEMBL537413

SCHEMBL537413

c1ccc2c(c1)ccc1nc3ccccc3n12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
PBRM1 Q86U86 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 7/20 0.41
HPGD P15428 6/20 0.41
HSD17B10 Q99714 4/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 3/20 0.41
POLB P06746 2/20 0.41
CSNK1A1 P48729 1/20 0.41
CLK2 P49760 1/20 0.41
LIMK1 P53667 1/20 0.41
DYRK1A Q13627 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 6/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31021114 1.00 SMN1; SMN2 (0.52) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
Hydrochloric Acid SCHEMBL537828 0.98 SMN1; SMN2 (0.50) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
Hydrochloric Acid SCHEMBL537827 0.98 SMN1; SMN2 (0.50) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
SCHEMBL23149860 0.82 PDE10A (0.43) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
SCHEMBL29344323 0.81 SMN1; SMN2 (0.36) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
SCHEMBL22342408 0.81 CYP2A6 (0.41) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
Hydrochloric Acid SCHEMBL29618030 0.79 HTR3A (0.41) SMN1; SMN2L3MBTL1KDM4EHPGDHSD17B10
SCHEMBL15437780 0.78 SMN1; SMN2 (0.44) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
SCHEMBL23149861 0.78 ALDH1A1 (0.42) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD
SCHEMBL22342347 0.77 SMN1; SMN2 (0.36) SMN1; SMN2PBRM1L3MBTL1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230240136-A1 First and Second Organic Semiconductor Layer and Organic Electronic Device Comprising the Same NOVALED GMBH (DE) 2023-07-27 US claimed
WO-2021058761-A1 FIRST AND SECOND ORGANIC SEMICONDUCTOR LAYER AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2021-04-01 WO claimed
EP-3799143-A1 FIRST AND SECOND ORGANIC SEMICONDUCTOR LAYER AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME Novaled GmbH (DE) 2021-03-31 EP claimed
US-4124589-A OPTICAL BRIGHTENERS, FLUORESCENT DYES HOECHST AKTIENGESELLSCHAFT (DE) 1978-11-07 US claimed
EP-3696179-B1 COMPOUND AND AN ORGANIC SEMICONDUCTING LAYER, AN ORGANIC ELECTRONIC DEVICE AND A DISPLAY OR LIGHTING DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2024-07-17 EP disclosed
EP-3696179-B1 COMPOUND AND AN ORGANIC SEMICONDUCTING LAYER, AN ORGANIC ELECTRONIC DEVICE AND A DISPLAY OR LIGHTING DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2024-07-17 EP disclosed
EP-3696180-B1 COMPOUND AND AN ORGANIC SEMICONDUCTING LAYER, AN ORGANIC ELECTRONIC DEVICE AND A DISPLAY OR LIGHTING DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2023-10-04 EP disclosed
EP-3696180-B1 COMPOUND AND AN ORGANIC SEMICONDUCTING LAYER, AN ORGANIC ELECTRONIC DEVICE AND A DISPLAY OR LIGHTING DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2023-10-04 EP disclosed
US-20230240136-A1 First and Second Organic Semiconductor Layer and Organic Electronic Device Comprising the Same NOVALED GMBH (DE) 2023-07-27 US disclosed
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 US disclosed
US-20220407017-A1 Organic Electronic Device and Display Device Comprising the Organic Electronic Device as well as Organic Compounds for Use in Organic Electronic Devices NOVALED GMBH (DE) 2022-12-22 US disclosed
US-20220149290-A1 Compound and an Organic Semiconducting Layer, an Organic Electronic Device and a Display or Lighting Device Comprising the Same NOVALED GMBH (DE) 2022-05-12 US disclosed
EP-3667749-A1 ORGANIC LIGHT-EMITTING DEVICE LG CHEM, LTD. (KR) 2020-06-17 EP disclosed
EP-2414355-A2 FLUORESCENT CELLULAR MARKERS Zayas, Beatriz (US) 2012-02-08 EP disclosed
US-4219651-A FLUORESCENT DYES, OPTICAL BRIGHTENERS; CHEMICAL INTERMEDIATES HOECHST AKTIENGESELLSCHAFT (DE) 1980-08-26 US disclosed
US-4219651-A FLUORESCENT DYES, OPTICAL BRIGHTENERS; CHEMICAL INTERMEDIATES HOECHST AKTIENGESELLSCHAFT (DE) 1980-08-26 US disclosed
US-4219651-A FLUORESCENT DYES, OPTICAL BRIGHTENERS; CHEMICAL INTERMEDIATES HOECHST AKTIENGESELLSCHAFT (DE) 1980-08-26 US disclosed
US-4124589-A OPTICAL BRIGHTENERS, FLUORESCENT DYES HOECHST AKTIENGESELLSCHAFT (DE) 1978-11-07 US disclosed
US-4124589-A OPTICAL BRIGHTENERS, FLUORESCENT DYES HOECHST AKTIENGESELLSCHAFT (DE) 1978-11-07 US disclosed
US-4124589-A OPTICAL BRIGHTENERS, FLUORESCENT DYES HOECHST AKTIENGESELLSCHAFT (DE) 1978-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220407017-A1 Organic Electronic Device and Display Device Comprising the Organic Electronic Device as well as Organic Compounds for Use in Organic Electronic Devices AOX1, OR10J3, CYP2E1 SMN1; SMN2 3025/4885PBRM1 2322/4885L3MBTL1 3203/4885
US-20220149290-A1 Compound and an Organic Semiconducting Layer, an Organic Electronic Device and a Display or Lighting Device Comprising the Same OCIAD1, AOX1, OCIAD2 SMN1; SMN2 4078/4885PBRM1 2323/4885L3MBTL1 638/4885
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof CHEK2, CHEK1, ATM SMN1; SMN2 2929/4885PBRM1 907/4885L3MBTL1 552/4885
US-20230240136-A1 First and Second Organic Semiconductor Layer and Organic Electronic Device Comprising the Same OR10J3, AXIN2, POU2F1 SMN1; SMN2 2635/4885PBRM1 4110/4885L3MBTL1 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.